The RGX-202 Phase III data is a transformative catalyst that could drive significant upside if the FDA accepts a BLA for accelerated approval. However, the cash runway is tight (into early 2027) and the company will likely need to raise capital before a potential approval. Monitor the Q4 2026 sura-vec wet AMD data readout and the $100M AbbVie milestone payment expected in Q2 2026, which would extend the runway.
RGNX drugs
RGNX drug pipeline →- ▲ surabgene lomparvovec 7/10 Phase 3
- ◆ NAVSUNLI 6/10 BLA resubmission pending (accelerated approval) — prior BLA reached PDUFA Feb 8, 2026 and received a Complete Response L
- ◆ RGX-202 6/10 Phase 3 (pivotal topline complete; BLA submission planned)
- ▼ RGX-111 2/10 Phase I/II (on FDA clinical hold since January 2026)
- All RGNX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 14 $6.25entry
- T+1 · 6mo ago −8.41%α −7.18% · $5.72
- T+5 · 6mo ago +8.09%α +8.80% · $6.75
- T+20 · 5mo ago +6.65%α +7.50% · $6.66
- T+60 · 3mo ago +66.85%α +63.26% · $10.42
Price Chart
How similar events traded
Executive Summary
REGENXBIO reported Q1 2026 results with a net loss of $90.1M ($1.72/share) vs. net income of $6.1M a year ago, as revenue collapsed 93% to $6.4M due to the absence of a prior-year $70M Nippon Shinyaku milestone and ZOLGENSMA royalty expiration. The cash burn is severe ($150.5M remaining, funding into early 2027). However, the filing is dominated by positive topline Phase III data for RGX-202 in Duchenne: the primary endpoint was met with high statistical significance (93% of patients achieved >10% microdystrophin expression, p<0.0001), and a statistically significant correlation between expression and functional improvement supports a potential accelerated approval pathway in 2027. The clinical hold on RGX-121 was also lifted. The combination of transformative pipeline catalysts and deteriorating financials creates a mixed picture.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $6.4M vs $89.0M YoY, down 93% due to absence of $70M Nippon Shinyaku milestone and ZOLGENSMA royalty expiration
- Net loss $90.1M ($1.72/share) vs net income $6.1M ($0.12/share) in Q1 2025
- Cash, cash equivalents and marketable securities $150.5M as of March 31, 2026, down from $240.9M at Dec 31, 2025
- Cash runway into early 2027 based on current operational plans
- Phase III AFFINITY DUCHENNE trial of RGX-202 met primary endpoint: 93% of patients achieved >10% microdystrophin expression (p<0.0001)
- Statistically significant correlation between RGX-202 microdystrophin expression and functional improvement (NSAA, n=9)
- Company plans to pursue accelerated approval for RGX-202 with potential commercial launch in 2027
- FDA lifted partial clinical hold on RGX-121 for Hunter syndrome
- AbbVie-partnered sura-vec (ABBV-RGX-314) on track: first patient dosed in DR Phase IIb/III expected Q2 2026; subretinal wet AMD pivotal data expected Q4 2026
- Company will receive $100M milestone from AbbVie upon first patient dosed in NAAVIGATE study
Financial Impact
Revenue declined 93% YoY to $6.4M; net loss widened to $90.1M from net income of $6.1M; cash burn of $90.4M in Q1 2026
Risk Factors
- Cash runway only into early 2027; likely need for dilutive financing before potential RGX-202 approval
- RGX-202 accelerated approval path requires FDA acceptance of surrogate endpoint; regulatory risk remains
- Revenue base collapsed 93% YoY with ZOLGENSMA royalty expiration and no recurring product revenue
- RGX-121 CRL appeal ongoing; path forward uncertain despite clinical hold lift
- Competitive landscape in Duchenne gene therapy (Sarepta, Pfizer, Solid Biosciences)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-222768 |
| Document: 0001193125-26-222768-index.html | 0001193125-26-222768 |
| Document: 0001193125-26-222768.txt | 0001193125-26-222768 |
| 8-K Data (Synthetic) | 0001193125-26-222768 |
Track record
15 reports on RGNX
2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +29.65% at T+60 after the Jul 20, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.69 Now $7.32 −4.81% settles Feb 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.38 Now $7.32 +0.81% settles Feb 3
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $7.71 Now $7.32 −5.06% settles Feb 2
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.93 Now $7.32 +5.70% settles Jan 13
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $7.26 Now $7.32 +0.83% settles Jan 8
- Aug 27, 202611w ago Insider Buy Bullish 5/10 Entry $9.66 Now $7.32 −24.22% settles Nov 23
- Aug 25, 202611w ago 8-K Neutral 3/10 Entry $9.38 Now $7.32 −21.96% settles Nov 19
- Aug 6, 202614w ago 8-K Bullish 7/10 Entry $11.28 to $7.41 Now $7.32 −35.11% ▼ −34.31% −32.88% vs SPY
- Aug 3, 202615w ago Press Release Neutral 1/10 Entry $9.96 to $6.59 Now $7.32 −26.51% ▼ −33.84% −35.62% vs SPY
- Jul 20, 202617w ago 8-K Bearish 6/10 Entry $10.32 to $7.26 Now $7.32 +29.07% ▲ +29.65% +34.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers